Philadelphia Based Gallon Pharma Rounds Up $10m For Sleep Apnea Treatment
Galleon Pharmaceuticals, a biotech company based in the suburbs of Philadelphia has rounded up $10 million from investors to help fund clinical trials of a new therapy to help people control their breathing. Galleon Pharmaceuticals, which was tapped by GlaxoSmithKline’s SR One investment arm a few years ago as one of the most promising start-up biotechs in the country, believes that it is on track to develop a new therapeutic drug class to treat breathing problems like sleep apnea and COPD.
MedCity News reports that Galleon launched back in 2005 with a $500,000 seed round from the BioAdvance Biotechnology Greenhouse of Southeastern Pennsylvania. The biotech got started with technology licensed from the University of Louisville’s Dr. David Gozal. Galleon is run by Jim Mannion, a longtime biopharma excutive with experience running clinical trials and in business development.
Tagged with: Breathing • breathing problems • Clinical Trial • COPD • Philadelphia sleep apnea • Sleep Apnea • Sleep Apnea Therapy • Sleep Apnea Treatment
Filed under: Clinical Trials • COPD • Sleep • Sleep Apnea • Sleep Apnea Effects • Sleep Apnea Events • Sleep Apnea News • Sleep Apnea Treatment • Sleep Disordered Breathing • Sleep Problems
Like this post? Subscribe to my RSS feed and get loads more!
Trackbacks/Pingbacks